Medical services company MDS Mexico has launched a rapid test service for COVID-19 that uses blockchain technology to verify the results.
Medical services company MDS Mexico has launched a rapid test service for COVID-19 that uses blockchain technology to verify the results. According to a local media report iProUP News on October 17, MDS Mexico has launched a digital platform that allows its patients to access the latest results in real time. Results are also provided physically, including a QR code that can be scanned to review results and access the patient's vaccination history on the MDS Mexico blockchain.
MDS says it is implementing blockchain to protect clinical trial results, protect patient personal information, and prevent falsification of COVID test results. The MDS website says: “In order not to fake negative results, we have started to authorize SARS-CoV-2 detection tests with blockchain technology and cryptographic signatures that protect information in a unique, immutable and immutable QR code that can be verified worldwide. The test results uploaded to the MDS blockchain also contain the cryptographic signature of the doctor examining the test results.
MDS is not the first company in Mexico to introduce blockchain for digitized Covid test results. Mexico's National Chamber of Commerce (CANACO) announced a government-sponsored initiative to digitize vaccination records in collaboration with private blockchain technology company Xertify. In August, representatives from the blockchain industry in Australia also called for the introduction of a blockchain-based vaccine registry to stop the spread of fake COVID-19 vaccine passports online.
Over the past 60 years, the average life expectancy of newborns has increased by almost 20 years - from 52.5 to 72 years in 2018. We have seen a tremendous wave of technological innovations during that time: the advent of the Internet, medical breakthroughs and understanding better about public health initiatives have changed the course of human life. And with new technologies like blockchain and artificial intelligence now on the scene, we know that a more radical transformation is imminent. This destructive technology is paving the way for a longer and healthier life. To show you how far healthcare has come thanks to this technology, I want to highlight the cases of two unique companies, Insilico Medicine and Longgenesis. Together they show how the development of artificial intelligence for medical care has grown in parallel with the emergence of blockchain applications in the healthcare sector.
In 2014, longevity innovator Alex Zhavoronkov and his company Insilico Medicine contacted me. The company is based on a simple but radical premise: use AI to accelerate drug discovery and development. At that time, the use of AI was still emerging, both in public awareness and in its application in the medical field. But in the seven years since I invested in this company, AI has completely transformed research and development in the therapeutic sector. The rapid discovery and development of new therapies is a result of the tremendous amount of data they process to find the next best treatment. This data is resourceful and extensive, and comes from the genomic and proteomic sequences of real health care patients. With dozens of new drug candidates, they have demonstrated tremendous potential in using AI for data-driven healthcare.
However, Insilico's revolutionary progress was not without obstacles. Working with large amounts of data poses particular challenges in terms of centralization and security. Health data are usually scattered and collected. Each doctor, health center and hospital has its own silo and due to data protection regulations, data is usually only shared when it is necessary for patient care. The availability of synthesized patient data is critical to the success of Insilico's AI algorithm and is simply not available.
While looking for a solution to the security and centralization issues associated with this type of data, Alex and the team at Insilico Medicine immediately came across blockchain technology and a distributed ledger. The immutability of blockchain data sets and the ability to have multiple decentralized nodes to carry data into a public ledger offer solutions to complex patient data problems. This technology is what they are looking for, but they need a partner to build it with them. Insilico has formed a joint venture with leading European blockchain firm Bitfury (now one of the largest emerging technology companies on the continent) and founded a new company called Longenesis. The goal of Longenesis is clear: to create a blockchain health ecosystem that takes into account the sensitive requirements for health data and biotechnology research applications.
Longenesis designed a blockchain-based environment for healthcare/biotechnology stakeholders, including patient organizations, biomedical research teams, and research partners and sponsors. The nice thing about Longgenesis's decisions is that there is always a statement of approval. When patients consent to their data being shared for any purpose, there is consistent evidence of their consent.
Its first product, Curator, is used by hospitals and other care facilities to provide researchers with available data securely and consistently without compromising patient confidentiality. This feature allows researchers to view records without compromising the security of patient data. If a researcher or company is interested in using that data, the second product of Longgenesis Engage offers it. Engage also allows hospitals and researchers to quickly engage patients in new medical studies and research by recording current patient consent. Whether AI is used to analyze new medical test data or "old" medical record data, patients know this and can choose consent if they find it convenient. Longenesis has implemented this solution in public hospitals, government biobanks and others. His work gives artificial intelligence companies like Insilico Medicine access to vast amounts of data that can be used to analyze artificial intelligence, leading to more treatments and drug discovery.
While I've highlighted two companies here, there are thousands of start-ups, research institutes, and stellar doctors working tirelessly to increase people's life expectancy. They can all benefit from the unlocked blockchain data and analytical power of artificial intelligence. The average hospital generates 760 terabytes of data per year, but 80% of that valuable data is unstructured and inaccessible to researchers. It must remain protected and the patient must permanently consent to its use. This disorder stops progress in all aspects of medicine. The combination of blockchain and AI can share that data for analysis, facilitate patient consent, track clinical data usage, and more.
Without blockchain for artificial intelligence, it lacks the ethical resources and protected biomedical data needed to find new solutions. Without artificial intelligence, large amounts of blockchain-protected data remain secure, but cannot be used for research. Progress comes when these innovations work together, just as important public health initiatives have succeeded in recent decades thanks to the advent of the World Wide Web. Hence our goal should be a more complete presentation of this technology to the market so that longevity oriented treatments are available to all.